Dare Bioscience, Inc.
July 14, 2025 - by Joey Ramson
$DARE is leading the Prism MarketView Women’s Health index today after announcing a positive update in results from its Phase 3 clinical trial of Ovaprene®, a hormone-free monthly contraceptive.
